HoneyNaps Expands into Boston’s Kendall Square, Accelerating Global Partnerships in AI Sleep Healthcare
New office in Boston-Cambridge innovation hub to expand partnerships with healthcare and life sciences leaders Supported through a Korea Health Industry Development Institute global expansion program Strategic move expected to accelerate commercialization, clinical collaborations, and market access in the United States BOSTON, April 28, 2026 /PRNewswire/ -- HoneyNaps, an AI-powered sleep healthcare company specializing in sleep diagnostics...
Kuching to Host Malaysia’s First CIFA Regional Symposium
KUCHING, Malaysia, April 28, 2026 /PRNewswire/ -- Malaysia has been selected to host the Consortium of Institutes on Family in the Asian Region (CIFA) Regional Symposium 2026, co-organised by the National Coalition for Mental Wellbeing (NCMW) Malaysia and CIFA Hong Kong, with Kuching making history as the first city in the country to host the event. ...
From Dalian to the Country: Neutech Group Reshapes Intelligent Elderly Care with “City-Level Elderly Care Service Platform”
HONG KONG and DALIAN, China, April 27, 2026 /PRNewswire/ -- At 7:00 a.m. in Dalian, Ms. Zhou opened the "Dalian Intelligent Elderly Care Service Platform" mini program in her home at Dahua Jinxiuhuacheng. She was booking an assisted bathing service for her semi-disabled father. Just after 10:00 a.m., a professional bathing assistant arrived on time with the necessary equipment....
Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
HONG KONG, April 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, has secured multiple authoritative updates and upgrades across first-line and later-line settings in the officially updated 2026 Chinese Society of Clinical Oncology (CSCO) Guideline for the Diagnosis and Treatment of Non-Small Cell Lung Cancer...
3Shape Receives FDA 510(k) Clearance for 3Shape Dx Software
COPENHAGEN, Denmark, April 28, 2026 /PRNewswire/ -- 3Shape today announced that the U.S. Food and Drug Administration (FDA) has granted FDA clearance for its Dx Software following a review completed on April 10. 2026. The 510(k) Premarket Notification allows Dx (R1) software to be commercially available in the United States for use by qualified dental professionals in dental clinics to aid...
HistoIndex Extends Access To Its MASH Diagnostic Offering Through New Partnerships In Texas And California
SINGAPORE, April 28, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced the continued expansion of its commercial partnership network in the United States with the addition of two new hepatology and gastroenterology centers - Houston Research Institute (HRI) Kingwood and Knowledge Research Center (KRC) in Orange, California. HistoIndex is...
Australian company unlocks a new era for women’s health globally with an innovative delivery system for Female testosterone in women with low libido
Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product Phase I and II clinical trials completed. Phase III to be done in co-development with global partners. Unique, Australian developed unique Patchless Patch™ delivery technology MELBOURNE, Australia, April 28, 2026 /PRNewswire/ -- Acrux is a successful Australian pharmaceutical company that develops innovative...
BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE
Key Highlights: An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study...
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan
TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan. SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, sustained manner to reduce restenosis and restore vessel function. The SELUTION SFA Japan clinical...
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces an educational webinar exploring the evolution of PSMA-targeted radionuclide therapy and Telix's differentiated, multi-product approach to treating prostate cancer across the disease continuum. Dr. David N. Cade, Telix Group Chief Medical Officer will host...
